Subscribe To
molecular partners to present initial data from ongoing phase 1/2a trial of mp0533 for patients with relapsed/refractory aml and aml/mds at the 65th ash annual meeting and exposition
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR ...
November 2, 2023, 2:00 am
molecular future (mof) showcasing remarkable journey
molecular Future (MOF), a leading digital asset investment service, invites the world to revisit its dy...
November 1, 2023, 6:20 pm
Zyversa therapeutics announces publication in molecular neurobiology reinforcing data demonstrating that inflammasome asc inhibitor ic 100 attenuates the inflammatory response causing neuronal damage
molecular Neurobiology publication demonstrated that NLRP3 inflammasomes have an important role in the ...
November 1, 2023, 12:07 pm
Why is mainz biomed (mynz) stock moving today?
Mainz Biomed (NASDAQ: MYNZ ) stock is on the move Wednesday after the molecular genetics cancer diagno...
November 1, 2023, 8:40 am
Why is cardio diagnostics (cdio) stock up 45% today?
Shares of cardiovascular medicine specialist Cardio Diagnostics (NASDAQ: CDIO ) are skyrocketing on Tuesday following the announcement of a key deal. ...
October 31, 2023, 3:56 pm
Context therapeutics reveals ‘encouraging' preclinical data for ctim-76 tumor treatment
Context Therapeutics (NASDAQ:CNTX) Inc has announced what it called encouraging preclinical data regarding its preclinical asset, CTIM-76, a Claudin 6...
October 31, 2023, 10:12 am
Dmtk shareholders: contact robbins llp for information regarding the class action against dermtech, inc.
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) — Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons and e...
October 30, 2023, 10:19 pm
molecular partners interim management statement q3 2023: continued validation seen across the …
Financial and Business Outlook For the full year 2023, at constant exchange rates, the Company expects total expenses of CHF 65-70 million, of which a...
October 26, 2023, 9:14 pm
Monte rosa therapeutics announces $25 million registered direct offering, priced at- the-market under nasdaq rules
BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel ...
October 26, 2023, 8:30 pm
Clarkson professors awarded $749,000 usda grant to develop technology to remove phosphate from agricultural fields and prevent nutrient pollution
Potsdam, NY, Oct. 25, 2023 (GLOBE NEWSWIRE) — Silvana Andreescu, Egon Matijevic Endowed Chair Professor of Chemistry and Bio...
October 25, 2023, 5:22 pm
Moderna and caris life sciences partner to develop mrna oncology therapeutics
Moderna Therapeutics Inc (NASDAQ:MRNA) has teamed up with Texas-headquartered private precision medicine and m...
October 24, 2023, 10:21 am
Transplant diagnostics market surges at 7.2% cagr towards usd 8.3 billion by 2032 | market.us
In 2022, molecular assays led in technology, reagents topped product & service, solid organ transplants...
October 19, 2023, 1:52 pm
Clarkson university researchers awarded nysp2i grant to develop sustainable food packaging and present at “keep it fresh!” symposium
POTSDAM, NY, Oct. 18, 2023 (GLOBE NEWSWIRE) — Silvana Andreescu, Egon Matijević Endowed Chair of Chemistry and Bio...
October 18, 2023, 5:13 pm
Here's why you should retain qiagen (qgen) stock for now
Investors are optimistic about QIAGEN's (QGEN) growth in the molecular diagnostics business and the lat...
October 18, 2023, 12:02 pm
Shareholder alert: robbins llp informs shareholders of class action filed against dermtech, inc. (dmtk)
SAN DIEGO, Oct. 16, 2023 (GLOBE NEWSWIRE) — Robbins LLP informs investors that a shareholder filed a class action lawsuit on behalf of persons and e...
October 17, 2023, 3:05 am
Biontech to present multiple program updates across modalities at esmo congress 2023
MAINZ, Germany, October 16, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data across its oncology pipeline, c...
October 16, 2023, 3:30 am
Coherus announces toripalimab data at 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics
— Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1 ...
October 14, 2023, 4:30 pm
Cogent biosciences presents preclinical data highlighting precision oncology pipeline at the 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics
– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantage...
October 14, 2023, 4:30 pm
Prelude announces multiple clinical and preclinical poster presentations at aacr-nci-eortc international conference
WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage pre...
October 14, 2023, 4:30 pm
Olema oncology kat6 inhibitor compounds demonstrate potent anti-tumor activity
Preclinical data to be presented at the 2023 AACR-NCI-EORTC International Conference on molecular Targe...
October 12, 2023, 11:01 am